Skip to main content
HHS Author Manuscripts logoLink to HHS Author Manuscripts
. Author manuscript; available in PMC: 2021 Dec 3.
Published in final edited form as: Clin Infect Dis. 2020 Dec 3;71(9):2527–2532. doi: 10.1093/cid/ciaa234

Modeling Infectious Diseases in Healthcare Network (MInD-Healthcare) Framework for Describing and Reporting Multidrug Resistant Organism and Healthcare-Associated Infections Agent-Based Modeling Methods

Rachel B Slayton 1, Justin J O’Hagan 1, Sean Barnes 2, Sarah Rhea 3, Rainer Hilscher 3, Michael Rubin 4, Eric Lofgren 5, Brajendra Singh 1, Alberto Segre 6, Prabasaj Paul 1; CDC MInD-Healthcare Program
PMCID: PMC7871347  NIHMSID: NIHMS1667519  PMID: 32155235

Abstract

Mathematical modeling of healthcare associated infections (HAIs) and multidrug resistant organisms (MDROs) improves our understanding of pathogens transmission dynamics and provides a framework for evaluating prevention strategies. One way of improving the communication among modelers is by providing a standardized way of describing and reporting models thereby instilling confidence in the reproducibility and generalizability of such models. We updated the Overview, Design concepts, and Details protocol developed by Grimm et al. for describing agent-based models (ABMs) to better align with elements commonly included in healthcare-related ABMs. The MInD-Healthcare framework includes the following nine key elements: 1. Purpose and scope; 2. Entities, state variables, and scales; 3. Initialization; 4. Process overview and scheduling; 5. Input data; 6. Agent interactions and organism transmission; 7. Stochasticity; 8. Submodels; 9. Model verification, calibration, and validation. Our objective is that this framework will improve the quality of evidence generated utilizing these models.

I. Framework purpose and audience

Healthcare-associated infections (HAIs) are associated with substantial morbidity, mortality, and costs [1, 2]. Mathematical modeling transmission of HAI pathogens and multidrug resistant organisms (MDROs) improves our understanding of the dynamics of the spread of pathogens, provides a framework for evaluating prevention strategies, and can accelerate prevention efforts [3]. Instilling confidence in the reproducibility and generalizability of models is a challenge that may be addressed through clear and thorough communication of the underlying methodology.

The International Committee of Medical Journal Editors has compiled recommendations for best practices for conducting and reporting high-quality scholarly work. Reporting guidelines utilized for different types of study designs include STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) for observational studies and Consolidated Standards of Reporting Trials (CONSORT) for randomized trials [4, 5]. However, there is a paucity of best practices for reporting HAI and MDRO transmission modeling studies to biomedical journals. As transmission modeling becomes increasingly prominent and findings are used to inform public health practice, a common framework for reporting would strengthen the knowledge base and acceptability of findings from such studies [6, 7], analogous to recent efforts to improve modeling of human papillomavirus-related cancer control [8].

In 2017, the Centers for Disease Control and Prevention created the Modeling Infectious Diseases in Healthcare Network (MInD-Healthcare), a consortium of investigators collaboratively developing and using mathematical models to investigate the spread and prevention of HAIs and MDROs. This document describes the MInD-Healthcare Framework and aims to improve communication among mathematical modelers about their respective agent-based models (ABMs). We specifically focus on transmission of HAI pathogens and MDROs, though there is substantial overlap with describing other infectious diseases. With an increasing proportion of ABMS among all HAI transmission models this framework is focused on ABMs in contrast to other models (e.g., compartmental models) for which complete mathematical specification is provided for methodological transparency [9]. However, the guiding principles are generalizable. This framework can be utilized by epidemiologists to better understand the methods used by mathematical modelers and appropriately interpret modeling studies’ results. This framework is an adaptation of the Overview, Design concepts, and Details (ODD) developed by Grimm, et al. to increase transparency and reproducibility of modeling methods in the context of ecological modeling [10, 11]. The ODD framework has infrequently been used to describe HAI ABMs, although it has improved methodological clarity when employed [1214]. The MInD-Healthcare Framework aims to align the traditional ODD with elements commonly included in healthcare-related ABMs and adopt terminology commonly used by epidemiologists to describe infectious disease processes.

II. Framework elements:

The framework is composed of nine elements: 1. Purpose and scope; 2. Entities, state variables and scales; 3. Initialization; 4. Process overview and scheduling; 5. Input data; 6. Agent interactions and organism transmission; 7. Stochasticity; 8. Submodels; 9. Model verification, calibration, and validation. See Table 1 for a checklist for users of this framework. Each element should be described clearly and concisely utilizing tables and diagrams, where appropriate.

Table 1:

Framework Elements

Element Checklist Item and Brief Definition Reported on Page No
1. Purpose and scope Purpose: specify the primary problem under consideration or the objective(s) of the study.
Scope: specify the boundaries for which dynamics will included and which are ignored.

__________
2. Entities, state variables, and scales Describe each entity, state variable, and scale.
Entity: a distinct or separate object or actor that behaves as a unit; may interact with other entities or be affected by external environmental factors. Each entity’s current state is characterized by its state variables.
State variable: attribute which performs at least one of the following functions: distinguishes an entity from other entities of the same type or category, or traces how the entity changes over time.
Scale: temporal and spatial resolutions and extents of the model.


__________
3. Initialization Describe the initial states of the model entities and environment, (i.e., at time t = 0) including how many entities of each type are present initially and the exact values of their state variables (or how they were set stochastically).
__________
4. Process overview and scheduling Process overview: specify who (i.e., what entity) does what (i.e., what actions are executed) and who is affected (i.e., which entities and state variables).
Scheduling: the order in which actions are taken and the order in which the effects of those actions are realized.

__________
5. Input data Describe whether the model uses input from external sources such as data files or other models to represent processes that change over time.
__________
6. Agent interactions and organism transmission Agent interactions: specify both direct interactions in which individuals encounter and affect others and any indirect interactions.
Organism transmission: describe how pathogen transmission is specified, including which interaction types result in changes to health states (e.g., incident colonization, infection transmission).

__________
7. Stochasticity Describe if stochasticity is part of the model and the major underlying reasons including which elements are modeled as fully stochastic, partly stochastic, or deterministic.
__________
8. Submodels Describe the equations and algorithms used in the submodels. Include tables of parameter definitions, units, and values used. __________
9. Model verification, calibration, and validation Describe the processes of verification, calibration, and validation.
Verification: process of ensuring the model was implemented correctly and meets the specifications of the model design.
Calibration: process of tuning the model parameters so that the model output matches a selected set of statistics from the real-world system or from simulated data.
Validation: process of evaluating how well the model represents the underlying truth of the real-world process it aims to represent.


__________

We strongly encourage using this checklist in conjunction with “Modeling Infectious Diseases in Healthcare Network (MInD-Healthcare) Framework for Describing and Reporting Multidrug Resistant Organism (MDRO) and Healthcare-Associated Infections (HAIs) Agent-Based Modeling (ABM) Methods” for important clarifications on all included elements. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see https://www.cdc.gov/hai/research/MIND-Healthcare.html

1. Purpose and scope[10]:

The purpose of a model is grounded by the primary objective(s) of the study, and the potential impact of the model-driven insights on clinical practice. The scope provides boundaries for which dynamics will be included and therefore the external validity of the model. The purpose and scope should align with each other and drive the description of the remaining framework elements. The purpose and scope of a model are typically described in the introduction of an article because they provide critical context for understanding why the model was developed and provide a guide for what to expect in the following model description. This element contains a summary description and justification for the model’s level of complexity and its intended use.

2. Entities, state variables, and scales[11]:

An entity is a person or object that may interact with other entities or be affected by external environmental conditions. The entities of an ABM (e.g., patients, healthcare personnel (HCP)) are characterized by a set of state variables. A state variable is an attribute which performs at least one of the following functions: it distinguishes an entity from other entities of the same type or traces how the entity changes over time. State variables may also be global and accessible to all entities. Scales refer to the temporal and spatial resolutions of the model and how influence they influence the representation of transmission (e.g., minimum duration for contact) [15]. Modelers should describe what kinds of entities are in the model and by what state variables or attributes they are characterized.

At any point in time, the state variables provide a snapshot of the model, with sufficient information to restore and restart the model from that instant. State variables can change over time (e.g., use of an antibiotic) or remain constant (e.g., sex, physical location of a hospital). Patient-level state variables should be epidemiologically meaningful and comparable to data available in electronic medical records (e.g., patients’ treatment statuses with each class of antibiotic could be included as state variables (e.g., neither, only penicillin, only fluoroquinolone, both), but ‘receipt of 2 antibiotic classes’ would not be considered a state variable). Health states are a set of state variables that represent the underlying natural history of disease processes. These health states may include, but are not limited to, susceptible, asymptomatically colonized, infected and infectious, and recovered. The health states that are modeled may vary by agent type (e.g., HCP may only become transiently colonized whereas patients progress to infection).

Many ABMs include the following types of entities and their associated state variables:

  • Agents. A model can have different types of agents; individuals can be considered agents and may be further differentiated in categories (e.g., patients, HCP). There may even be different sub-types within a category, (e.g., nurses, physicians). Agents are not limited to humans (e.g., pathogens or facilities). Example state variables of agents include: identity number (i.e., even if all other state variables would be the same, the agent would still maintain a unique identity), demographics (e.g., age, sex), location (e.g., assigned unit within a hospital), and comorbidities (e.g., previous antibiotic use).

  • Spatial units. Spatial units are often used to model the state of specific spatial locations within a hospital (e.g., patient room, unit) and are referred to as grid cells or patches. Example state variables of spatial units include: location, size, list of agents within the spatial unit, and descriptors of physical environmental conditions (e.g., surface type) within the spatial unit. Some overlap of roles can occur; for example, a spatial unit used to model a patient room may be an entity with its own state variables (e.g., likelihood of surfaces to become and remain contaminated) but may also function as a location, and hence a state variable, of patients.

  • Collectives and cohorts. We group entities with common state variables together. These groups of entities can have distinct behaviors, so it may make sense to distinguish them as a defined group (e.g., entire healthcare facilities, groups of HCP within a unit, or households). A collective is a group that is usually characterized by the list of its agents, and by specific actions that are only performed by the collective, not their constitutive entities (e.g., a hospital ward made up of spatial unit subcomponents in which certain agent to agent interactions can only occur). In contrast, a group of agents that are only considered as a unit of analysis (and do not have distinct behavior) are referred to as a cohort (e.g., ICU patients to aid in model verification, calibration, and validation).

In describing spatial and temporal scales it is important to specify what the model’s units represent in reality, both within and among healthcare facilities. For temporal scale: describe time period being modeled (e.g., 5-year period or specific calendar years 2011–2015). Describe time as discrete steps (e.g., day) or as a continuum over which both continuous processes and discrete events can occur. Describe if timescales vary by agent class and at which timestep events occur. For spatial scale: Describe if agents operate and interact within a single ward, across an entire healthcare facility, or across a network of healthcare facilities and the community. Describe if the model explicitly represents a geographic area.

3. Initialization [11]:

Results generated from ABMs can depend significantly on the initial conditions of the model. Initialization describes the starting states of the model entities and environment (i.e., at time t = 0 of a simulation run), including how many entities of each type are present initially and the exact values of their state variables or how they were set stochastically. Describe if initialization is always the same or varies between simulation runs. Are the initial values chosen arbitrarily or based on data? If the latter, references to those data should be provided. It may not be possible to accurately replicate model results unless the initial conditions are known. Different models, and different analyses using the same model, can of course depend quite differently on initial conditions. Sometimes the purpose of a model is to analyze consequences of its initial state, while other times modelers aim to minimize the effect of initial conditions on results (e.g., excluding the output from a predetermined warmup period). These considerations should be described explicitly and align with the overall objective of the study. If a random number seed is used for stochastic elements, this section is the appropriate place to specify the value of that seed.

4. Process overview and scheduling [11]:

The simulation of an ABM relies extensively on an explicitly-defined schedule for how model processes are executed. Processes can be defined by who (i.e., what entity) does what (i.e., what actions are executed) and who is affected (i.e., which entities and state variables). Scheduling determines the order in which actions are taken, as well as the order in which the effects of those actions are realized. Many ABMs represent time in discrete steps, while others treat it as a continuous variable [16].

Describe if the model is a hybrid or combined model (i.e., including compartmental components). In this element only the self-explanatory names of the model’s processes should be listed: ‘move’, ‘update plots’, etc. These names are then the titles of the submodels that are described in section 8, ‘Submodels’. As Grimm et al. defined, processes are performed either by one of the model’s entities (e.g., move), or by a higher-level controller (i.e., an observer) that performs actions such as updating plots or writing output to files. To handle such higher-level processes, ABM software platforms like Repast [17] and NetLogo [18] include the concept of the ‘Model’ or ‘Observer’. By ‘in what order?’ we refer to both the order in which the different processes are executed and the order in which a process is performed by a set of agents. For example, HCP visiting a patient we specify the order in which HCP attempt to wash their hands, wear personal protective equipment, and touch the patient and environment. We specify, relative to other processes modeled, whether HCP perform hand hygiene in a random order, a fixed order, or a HCP type-sorted order. Differences in such ordering (e.g., HCP visits to patients) can have a very large effect on model outputs [19, 20]. When processing a particular action, an entity’s state can be updated immediately (asynchronous updating), or the update can be stored until all entities have executed the process, at which point all entity states are updated simultaneously (synchronous updating).

For this element, only an overview is required to provide an understanding of how the ABM is simulated (e.g., visit patient, update environment). The specific details of these processes are reserved for the submodels element. Except for very simple models, authors should provide the full model code or at a minimum pseudo-code to fully describe the schedule, so the model can be replicated. Ideally, the pseudo-code corresponds fully to the actual ABM code.

5. Input data [11]:

Describe whether the model uses input from external sources such as data files or other models to represent processes that change over time. In models of real systems, dynamics may be driven in part by a time series of environmental variables, sometimes called external forcings; for example, seasonality of disease or associations with environmental factors that could affect the hospital infrastructure (e.g., legionellosis and rainy weather seasons, daily shift schedules of HCP). ‘Driven’ means that one or more state variables or processes are affected by how these environmental variables change over time. However, these environmental variables are inputs and are not, themselves, affected by the internal variables of the model. Often it makes sense to use observed time series of environmental variables so that their statistical qualities (e.g., mean, variability, temporal autocorrelation) are realistic. Alternatively, external models can be used to generate input (e.g., a set of seasonal environmental conditions) [21]. Obviously, to replicate an ABM, any such input has to be specified and the data or models provided, if possible. The publication of input data for some simulations may be constrained by confidentiality considerations. Where such concerns exist, inclusion of pseudo data ought to be considered. If these input data are obtained through an application program interface (API) to another model or data provider, details on how this API can be accessed should be provided. If a model does not use external data, this element should nevertheless be included, using the statement: ‘the model does not use input data to represent time-varying processes.’ Note that ‘Input data’ does not refer to parameter values or initial values of state variables.

6. Agent interactions and organism transmission [11]:

Describe the kinds of interactions among agents that are assumed. Include a description of both direct interactions (e.g., in which individuals encounter and affect others) and indirect interactions (e.g., patients sharing the same care team). Provide details on how transmission is specified, including which interactions result in changes to health states (e.g., in a simple flow chart). How do agents react to the interactions, or lack thereof, with other agents and the processes that they undergo? How do the pathogen characteristics influence transmission? Is feedback from previous processes incorporated into future processes? Are dynamic responses based on exceeding some minimum threshold?

7. Stochasticity [3]:

Often times we choose to model variability in a parameter or process without fully representing all the underlying mechanisms which account for that variability occurring. A simplified approach is to incorporate stochastic elements which randomly draw numbers to change parameters or processes. ABMs are inherently stochastic, though they may contain deterministic elements (e.g., a module describing room contamination deterministically may output contamination level as a parameter value in an ABM more broadly). Demographic stochasticity, where only whole individuals, as opposed to fractions of individuals, can undergo changes (e.g., birth, death, disease state changes) is a mechanistic basis for including stochasticity in mathematical models and is especially relevant small populations [17]. What elements of the submodels are modeled fully stochastically, partially stochastically, or deterministically? Why are elements modeled this way? Is stochasticity used, for example, to reproduce variability in processes for which it is important to model the actual causes of the variability? How many model replications are utilized and how was this number determined?

8. Submodels [11]:

All submodels should be presented completely and in detail (e.g., utilizing the applicable framework elements). Submodels are described at a high level in the process overview and scheduling, although specific details of these processes are described here. The factual description of the submodel, (i.e., equation(s) and algorithms), should be described. If parameterization is not discussed outside of the description based upon this framework, it can be included here. The parameter definitions, units, and values used should be presented in tables. The purpose of including this information is to prevent the description from seeming ad hoc and to strengthen model credibility. Justification can be very brief in the earlier sections, but the complete description of submodels is likely to include references to relevant literature, as well as independent implementation, testing, and analysis of submodels. Additionally, in most cases it will be necessary to have simulation experiments or a model analysis section following the model description.

9. Model verification, calibration, and validation:

Verification is the process of ensuring the model was implemented correctly. Calibration is the process of tuning the model parameters so that model output matches a selected set of statistics from the real-world system or simulated data and is possibly conducted in tandem with validation (e.g., incident infections hospital-wide). Validation is the process of evaluating how well the model represents the underlying truth of the process it aims to represent. What is the process of model verification? What is the process for model calibration? What are the calibration targets and on what information are they based? What is the process for model validation?

Sensitivity analysis may be a part of multiple processes. Sensitivity analysis is the process of determining which model parameters and structures have the most significant effect on model outputs. Uncertainty analysis is the process of evaluating how the uncertainty of model parameter values may affect the model’s output.[22] The precision with which parameters can be measured in the real-world impacts the reliability of model results generated using those estimates [3]. Therefore, uncertainty analysis relates to validation and calibration. Sensitivity analysis may be performed for verification (e.g., extreme value test) or validation (e.g., analyzing the impact of increasing hand hygiene compliance on acquisition rates) or calibration (e.g., choosing a wider range for certain parameters to be chosen from, fixing non-calibrated parameters to different plausible values, employing a different fitting method). What sensitivity analyses were conducted? What uncertainty analyses were conducted?

III. Interpretation

The MInD-Healthcare Framework was developed as a set of best practices for conducting and reporting transmission modeling studies, in particular those utilizing ABMs. It primarily aims to improve communication among mathematical modelers about their respective ABMs and builds upon the ODD protocol [10]. By increasing methodological transparency, we hope this framework will improve quality and reproducibility of the evidence generated by these models, just as development of the CONSORT guideline improved completeness of reporting of randomized controlled trials [23]. Additionally, this framework can facilitate multi-model comparisons by aiding in harmonization, systematic exploration of variability, and pooling of results [24].

High-quality scientific literature provides a complete methodological description and increased certainty for decision makers. Mathematical models are often criticized as being “black boxes” because they provide a limited methodological description. Adoption of these standards will enable consumers of modeling studies to better understand the methods and accompanying strengthens and limitations of these studies. Increased transparency also ought to improve the interpretation of modeling studies and adoption of recommendations based upon these studies. The MInD-Healthcare Framework should be reevaluated and revised in the future to consider evolution of the field, generation of new evidence, and incorporate feedback from those using this framework.

Funding:

This work was supported by the U.S. Centers for Disease Control and Prevention (5 U01 CK000531-02).

Footnotes

Publisher's Disclaimer: Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

References

  • 1.Antibiotic Resistance Threats in the United States, 2013 In: Prevention USCfDCa. Atlanta, GA, 2013. [Google Scholar]
  • 2.Scott RD. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention. 2009.
  • 3.Railsback SFG V Agent-based and Individual-Based Modeling: A Practical Introduction. Princeton, NJ: Princeton University Press, 2012. [Google Scholar]
  • 4.von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370(9596): 1453–7. [DOI] [PubMed] [Google Scholar]
  • 5.Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Tracy M, Cerda M, Keyes KM. Agent-Based Modeling in Public Health: Current Applications and Future Directions. Annu Rev Public Health 2018; 39: 77–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Willem L, Verelst F, Bilcke J, Hens N, Beutels P. Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006–2015). BMC Infect Dis 2017; 17(1): 612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Canfell K, Kim JJ, Kulasingam S, et al. HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. Papillomavirus Res 2019; 8: 100184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.van Kleef E, Robotham JV, Jit M, Deeny SR, Edmunds WJ. Modelling the transmission of healthcare associated infections: a systematic review. BMC Infect Dis 2013; 13: 294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Grimm V, Berger U, Bastiansen F, et al. A standard protocol for describing individual-based and agent-based models. Ecological modelling 2006; 198(1–2): 115–26. [Google Scholar]
  • 11.Grimm V, Berger U, DeAngelis D, Polhill JG, Giske J, Railsback S. The ODD protocol: A review and first update. Ecological modelling 2010; 221(23): 2760–8. [Google Scholar]
  • 12.Lanzas C, Dubberke ER. Effectiveness of screening hospital admissions to detect asymptomatic carriers of Clostridium difficile: a modeling evaluation. Infect Control Hosp Epidemiol 2014; 35(8): 1043–50. [DOI] [PubMed] [Google Scholar]
  • 13.Bintz J, Lenhart S, Lanzas C. Antimicrobial Stewardship and Environmental Decontamination for the Control of Clostridium difficile Transmission in Healthcare Settings. Bull Math Biol 2017; 79(1): 36–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ferrer J, Salmon M, Temime L Nosolink: An Agent-based Approach to Link Patient Flows and Staff Organization with the Circulation of Nosocomial Pathogens in an Intensive Care Unit. Procedia Computer Science 2013; 18: 1485–94. [Google Scholar]
  • 15.Dawson DE, Farthing TS, Sanderson MW, Lanzas C. Transmission on empirical dynamic contact networks is influenced by data processing decisions. Epidemics 2019; 26: 32–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Grimm V, Railsback SF Individual-Based Modeling and Ecology. Princeton: Princeton University Press, 2005. [Google Scholar]
  • 17.Keeling MJ, Rohani P Modeling Infectious Diseases in Humans and Animals. Princeton, NJ: Princeton University Press, 2008. [Google Scholar]
  • 18.Wilensky U NetLogo. Evanston, IL: Northwestern University, 1999. [Google Scholar]
  • 19.Bigbee T, Cioffi-Revilla C, Luke S Replicating the classic Sugarscape in MASON Complex Behavior in Economics: Modeling, Computing and Mastering Complexity. Aix-en-Provence, France, 2006. [Google Scholar]
  • 20.Caron-Lormier G, Humphry RW, Bohan DA, Hawes C, Thorbek P Asynchronous and synchronous updating in individual-based models. Ecological modelling 2008; 212: 522–7. [Google Scholar]
  • 21.Eisinger D, Wiegand K. SERGE: A spatially explicit generator of local rainfall in southern Africa. South African Journal of Science 2008; 104: 37–42. [Google Scholar]
  • 22.Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012; 32(5): 722–32. [DOI] [PubMed] [Google Scholar]
  • 23.Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev 2012; 1: 60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.den Boon S, Jit M, Brisson M, et al. Guidelines for multi-model comparisons of the impact of infectious disease interventions. BMC Med 2019; 17(1): 163. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES